Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ath – page 66

1 642 clinical trials in Ath, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ath at a glance
1 642
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 642 trials in Ath

Open in trial search

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Colitis ulcerative+1

Not recruiting

A study to evaluate the long-term safety and effectiveness of balinatunfib in adults with Crohn's disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Balinatunfib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Dermatitis atopic

Not recruiting

Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Cardiac failure

Not recruiting

Evaluation of Ziltivekimab in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ath

What the registry says about research in the country

01 Cardiovascular and Cerebrovascular Research

Clinical research in Ath addresses critical cardiovascular conditions, particularly focusing on cerebrovascular events. Investigations center on acute ischemic stroke and high-risk transient ischemic attack, conditions that represent significant causes of disability and mortality. These studies aim to evaluate novel therapeutic approaches designed to reduce the risk of recurrent ischemic events in patients who have experienced these serious cerebrovascular incidents.

  • Assessment of innovative pharmacological interventions for stroke prevention
  • Evaluation of treatment strategies to minimize recurrent cerebrovascular events
  • Investigation of therapeutic efficacy in acute cerebrovascular conditions
  • Research focused on improving outcomes for patients with transient ischemic attacks

The research underway seeks to establish safer and more effective treatment protocols for individuals at elevated risk of stroke, potentially improving long-term neurological outcomes and quality of life for affected patients.

02 Oncology and Gastrointestinal Cancer Research

Ath hosts clinical investigations in the field of oncology, with particular emphasis on gastrointestinal malignancies. Research efforts concentrate on locally advanced rectal cancer, examining treatment strategies tailored to specific patient populations. These trials explore different approaches to neoadjuvant therapy, which involves treatment administered before surgical intervention, aiming to optimize the balance between treatment effectiveness and patient safety.

  • Comparison of conventional neoadjuvant therapy versus total neoadjuvant therapy approaches
  • Evaluation of treatment efficacy and safety profiles in older cancer populations
  • Investigation of optimal timing and sequencing of chemotherapy and radiation therapy
  • Research on personalized treatment strategies for rectal cancer management

These studies are particularly significant as they address the unique needs of older patients with rectal cancer, seeking to identify treatment regimens that maximize therapeutic benefit while minimizing adverse effects in this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.